Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
14 nov. 2022 06h00 HE
|
Lumos Pharma, Inc.
- LUM-201, potentially the first oral medication for PGHD, met expectations in an interim analysis of two Phase 2 trials evaluating growth in Pediatric Growth Hormone Deficiency (PGHD) - - Interim...
Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference
26 sept. 2022 16h05 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials...
Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
31 août 2022 09h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials...
Lumos Pharma Announces Share Repurchase Program
16 août 2022 07h30 HE
|
Lumos Pharma, Inc.
-- Plan to Repurchase Up to $3 Million of Common Shares -- AUSTIN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (“The Company,” NASDAQ:LUMO), a biopharmaceutical company advancing...
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
09 août 2022 16h01 HE
|
Lumos Pharma, Inc.
-- Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in Q4 2022 -- -- Primary Outcome Readouts from Both Trials Anticipated 2H 2023 with Data in up to 24...
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022
27 juil. 2022 16h05 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its second quarter 2022 financial...
Lumos Pharma to Participate in Upcoming Investor Conferences
16 mai 2022 16h05 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
10 mai 2022 16h01 HE
|
Lumos Pharma, Inc.
--Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022-- --FDA Permits Treatment with LUM-201 Beyond 12...
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
05 mai 2022 09h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, initially targeting pediatric...
Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
26 avr. 2022 09h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Tex., April 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its first quarter 2022 financial results...